Ref: Syn/CS/SE/IP/2025-26/Dec/06

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 9191
CIN: L85110KA1993PLC014937
www.syngeneintl.com

December 17, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	**Scrip Symbol: SYNGENE**

Dear Sir/Madam,

Sub: Investor Presentation.

In continuation to our earlier intimation vide reference no. Ref: Syn/CS/SE/Reg 30/2025-26/ Dec/04 dated December 11, 2025 and in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the presentation which will be shared with the Investors and Analysts at the meeting to be held today i.e. December 17, 2025.

Kindly note that no additional information will be disclosed to Analysts or Investors other than the information presented earlier and already available in public domain.

The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

CHETHAN YOGESH
Digitally signed by CHETHAN YOGESH
Date: 2025.12.17 12:49:49 +05'30'

Chethan Yogesh
Company Secretary & Compliance Officer

Enclosed: Investor Presentation.

Syngene
Putting Science to Work

Webinar on Clinical Trials Market

- By Dr. Mrinal Kammili

17 Dec 2025

Safe Harbor Statement

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Agenda

Sr. no	Timing	Particulars	Led by
1	1:30 - 1:40 PM	Why this webinar Introduction to our inhouse expert - Dr. Mrinal Kammili	Nandini Agarwal
2	1:40 PM - 2:20 PM	• Clinical Trials Industry • Overview of Syngene's Translation and Clinical Research (T&CR) business	Dr. Mrinal Kammili
3	2:20 PM - 2:30 PM	• Q&A	Dr. Mrinal Kammili

Why this webinar

- In Q2 FY26, Syngene announced a deal for first global phase III clinical trial from a U.S.-based biotech company.
    - The trial will recruit patients across clinical sites in India and the U.S., reflecting Syngene's growing capabilities in the global clinical trials market
- We got many questions around understanding / further clarity of Translation and Clinical Research business (T&CR), operating models, industry and Syngene business in the segment
- This webinar is focused on providing more on the Clinical Trials research business, industry and Syngene offerings in the T&CR segment

Please refrain from asking any questions around specific Syngene financials

Our in-house expert for the webinar – Dr. Mrinal Kammili

Dr. Mrinal Kammili
Head, Translational & Clinical Research

- Joined Syngene in January 2025 – **part of the Syngene Executive Committee**
- Head of Translational & Clinical Research with over 27 years of experience in clinical research
- A medical doctor and AHA-certified intensivist
- Previously worked as Executive Director, Board Member, and Global Head of Business Development in Lambda Therapeutics
- Served on the Board of Novum Pharmaceutical Research Services, Lambda's U.S.-based subsidiary.
- Led various global operations, M&A, corporate strategy, and digital initiatives

Clinical Trials Market

Syngene | Putting Science to Work

Translational and Clinical Research forms a large and growing segment within the overall global CRDMO market

Global CRDMO market expected to grow at ~9% CAGR



Clinical CROs market forms ~30% of overall CRDMO market and growing at double digit

Key growth drivers of Clinical CRO market

1. **Increasing R&D Pipeline**: growing at ~7% CAGR; new drugs require clinical trials for regulatory approvals
2. **Outsourcing Acceleration**: Big pharma increasingly outsourcing R&D, Clinical trials and manufacturing *for cost control, speed, and expertise.*
3. ***Patient Diversity & Recruitment Pressure :*** Rising demand for multi-ethnic, multi-regional trials to meet regulatory and scientific requirements, driving broader recruitment strategies
4. ***Rise of virtual biotech companies with limited infrastructure and predominant reliance on CROs for integrated solutions***
5. ***Cost Advantage :*** lower costs vs. Western markets and large pools of treatment-naïve patients make outsourcing to APAC attractive

Source : Evaluate Pharma, Frost & Sullivan, IMAP (pharma sector update)
1. Includes Discovery and Pre-Clinical
2. Includes both Large molecule and Small molecule CDMO

Market Outlook – Rapid growth in APAC and India market driven by strong tail winds

APAC leads growth; North America still dominates with ~30% of the global clinical CRO market



North America remains the largest market

APAC & emerging markets increasing share, especially in early phase and patient-diverse studies

Level of attractiveness - Indian CRO market

Factor	Level of attractiveness	Future impact
	LOW – High	
Patient Pool		++
Study Timeline		++
Facilities & Infra		++
Reg. Environment		+
Quality of Data		+
Cost		++

India US Australia

Indian Clinical CRO market[1] – Exceeds global growth rate



India's clinical CRO market is projected to grow at 16% CAGR (2024 – 28), outpacing the global rate of 11% and In-line with APAC's 18% growth rate

Indian clinical CRO market – Factors driving growth

- Large Population & high disease burden – ***Access to Large & diverse subject pool***
- Availability of ***skilled workforce***, the count of clinical trial investigators has doubled from 2015 to 2022
- Reliable ***regulatory environment*** –New Drugs and Clinical Trials Rules (2019) – to fast-track accessibility of new drugs, foster clinical research in India
- ***Supportive geopolitical dynamics*** – China+1, US bio secure act
- India Provides significant ***cost advantage*** - ~40% to 60% compared to North America & Europe

Syngene

Source: Frost & Sullivan, Industry reports
[1] Includes BA/BE studies
2029 estimates for Indian Clinical CRO Market is unavailable

Indian market is fragmented and players with differentiated capabilities and strong regulatory data management experience have an edge

Global Clinical CRO players

IQVIA, ICON, ThermoFisher Scientific, Syneos Health, Fortrea, MEDPACE, Tigermed 泰格医药

Key players in Indian Clinical CRO space

Veeda Lifesciences, cliantha research, LAMBDA Research Accelerated, Vimta, Syngene Putting Science to Work

Key Success Factors

The Indian market is relatively fragmented in comparison to the global Caribbean clinical CRO industry which has large players

Key success factors for Indian players include:

- **Understanding of local market and regulations:** *Increased drug development complexities and heterogenous regulatory compliance for different markets*
- **Full-service offerings:** *Sponsors are increasingly seeking a comprehensive solution for all their drug development requirements*.
- **Access to large patient population and track record** *of delivering studies within the cost, timelines and global compliance standards*
- **Investments in new modalities:** *Emerging modalities such as biologics/ADC require deeper translational insights—multi-omics data, mechanistic biomarkers, advanced bioanalytical platforms*
- **Use and data and analytics:** *advanced digital platforms, data analytics, and AI-driven trial management, ensuring efficiency, precision, and data integrity at every stage*

Translational and Clinical Research forms an integral part of the overall drug discovery and development value chain



A — Translational Research

- Turning scientific discoveries into real health benefits
- Connects "Lab to clinic" or "bed to bedside " by generating data that improves predictability and reduces uncertainty in drug development

B — Phase I / First-in-Human (FIH)
First reality check in humans

- Conducted mostly in healthy volunteers; assess Safety and tolerability, PK/PD, dose escalation
- High attrition due to unexpected human response

C — Phase II
Proof of concept or failure

- Conducted in patients with the target disease or condition
- Assesses preliminary efficacy while continuing to evaluate safety
- Used to explore dose response, treatment regimen, and clinical endpoints

D — Phase III
Execution at scale

- Large, controlled clinical studies conducted in broader patient populations
- Designed to confirm efficacy and further characterize safety
- Data generated supports regulatory submission and labelling

Translational Science: anticipate uncertainty and de-risk before programme reaches the clinic



Past View

Translational science was seen as a handoff point Translating preclinical data into clinical hypotheses.

Today

It's the foundation for planning, resourcing, and executing drug development from the earliest stages

Pillars of translational sciences at Syngene



Patient based Clinical Trial



Syngene's T&CR business

Syngene | Putting Science to Work

Syngene's T&CR business is now a segment within our Research business

What does T&CR business include

Human Pharmacology Unit – Healthy volunteer early-phase BA/BE studies, drug-drug interaction studies, food effect studies, phase I studies (biosimilars, vaccines) **190 bed unit; 12 bed ICU**

Clinical Trial Services: Patient-based clinical trials across therapeutic areas and phases.

Bioanalytical services – Supporting safety and efficacy endpoint observations and Immunoassays for PK, PD, Immunogenicity and Biomarkers.

Central Lab Services – Safety analysis in healthy volunteer and patient-based clinical trials, biomarker analysis, global sample logistics with kit building.

Allied Services like Clinical Data Management, Biostatistics, Medical Writing and Regulatory Affairs

Syngene Strengths

→ ***Track Record and Expertise:*** *Completed 800 BA/BE studies for submissions in regulated markets. Extensive experience in managing global clinical trials across geographies with Regulatory & operational excellence*

→ ***Integrated Continuum:*** *Continuity across the value chain from early discovery and DMPK to toxicology, biomarkers, clinical development to reduce development friction and enables confident transition from bench to bedside*

→ ***Global Clinical Network:*** *Partnerships with 180+ sites in India and leading CROs in the U.S., U.K., Jordan, Europe, Australia, Srilanka and New Zealand for early and late phase trials worldwide*

→ ***Diversified Platform:*** *Comprehensive offerings to take molecules from discovery to commercialization supported by investments in new modalities and use of digital/AI for better efficiency*

→ ***State-of the-art infrastructure, FDA and EMA audited clinics*** *and bioanalytical labs, and CAP accredited Central Laboratory.*

T&CR: Part of our diversified platform encompassing Research Services, LM CDMO and SM CDMO

Research Services (CRO)

Discovery Services

Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs

SynVent - proprietary platform for Integrated Drug Discovery

SARchitect- proprietary platform for data visualization and analysis. Enables collaboration between scientific experts across geographies

Dedicated R&D Centers

Ring-fenced infrastructure for exclusive operations for an individual client

Dedicated multi-disciplinary team of scientists

Access to entire Syngene ecosystem for specialist research and development operations

T&CR

Comprehensive research services through trials conducted on both healthy volunteers and patients

- Human Pharmacology Unit (Phase I/BE studies)
- Clinical Trial Services – full solution provider for conducting global trials
- Translational services- a continuum from preclinical to clinical trials
- Regulated bioanalysis for large and small molecules
- Central Laboratory

Large Molecule CDMO

Process development

Manufacturing of large molecules for clinical/commercial supplies

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant facilities

State-of-the art Biologics manufacturing facilities with international presence

Small Molecule CDMO

Drug substance and drug product development

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing of small molecules for commercial supplies

State-of-the art API manufacturing facility

Operating models in T&CR

2 way Model	3 way Model
Direct Syngene-client engagement	Syngene + Client + Partner collaboration for global reach
End-to-end clinical trial solutions	Shared responsibilities for large scale multi region trials with diverse population subsets
The revenue is milestone based with contracts typically spanning 15 to 24 months	The revenue is milestone based, with contracts spanning longer timeframes depending on trial design

Strategic focus for the T&CR business

→ ***Support more complex and new modalities clinical trials***

→ ***3S formula*** *– strengthen, stabilize and streamline the existing functions and portfolio in near term*

→ ***Forward integration into subsequent phases of clinical trials*** *in mid to long term*

→ ***Accelerated Decisions, Reduced Risk:*** *Seamless integration of bioanalysis, translational science, and clinical development drives faster decisions and reduce risk*

→ ***Comprehensive clinical partner:*** *From biomarker driven early phase insights to global late phase regulated bioanalysis and clinical execution.*

Summary

T&CR part of Research Services	• T&CR enables better support decisions across the drug development lifecycle, **connecting discovery sciences and clinical services** • Foundation for planning, resourcing, and executing drug development from the earliest stages
Big and growing market	• Clinical Trials forms a large and growing segment within the overall global CRDMO market (~$60 bn global market; growing at 11% CAGR)
Right to win opportunity for Indian players	• APAC is fastest growing market with increasing share, especially in early phase and patient-diverse studies • India market also witnessing strong growth driven by availability of treatment naïve patient pools, cost benefits, change in regulatory regime, supportive geopolitical dynamics
Syngene differentiation	• Extensive experience in BA/BE studies; integrated platform; experience in managing global clinical trials; regulatory and operational excellence; adherence to global compliance standards

Q&A

- *Q&A focused on T&CR industry, business/operating model, better understanding of Syngene offerings in the segment*
- *We will not be to disclose any Syngene specific financials at this point of time*